On March 21, 2024 TriSalus Life Sciences Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, reported that the Company will present data from recent research findings at the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, to be held March 23-28, 2024, in Salt Lake City, Utah (Press release, TriSalus Life Sciences, MAR 21, 2024, View Source [SID1234641365]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TriSalus will share data on the technical feasibility and safety of Pressure-Enabled Drug Delivery (PEDD) procedures in hypovascular tumors and initial data regarding our Pancreatic infusion technology, which is currently 510(k) cleared by the U.S. Food and Drug Administration (FDA) and in the Phase 1 clinical trial with nelitolimod in locally advanced pancreatic cancer.

The TriSalus approach seeks to address many of the key challenges associated with delivering therapeutics to pancreas tumors. In contrast to the liver, pancreas arteries feeding tumors are difficult to access and venous access affords anatomic advantages. Additionally, pancreatic tumors exhibit a dense, desmoplastic stroma that limits the delivery of therapeutics. The technology is designed to address these mechanical barriers and challenges by modulating pressure and flow, incorporating real-time pressure sensing capability to optimize safety and delivery.

"The presentations featuring our PEDD approach illustrates that TriSalus is committed to and focused on transforming how therapeutics are delivered into biologically challenging liver and pancreas tumors. Mechanical barriers present in the tumor microenvironment, including high intra-tumoral pressure, may limit the performance of many therapeutic classes including embolics and immunotherapy. We look forward to our continued partnership with the interventional radiology community to improve outcomes in a variety of solid tumor indications," noted Steven C. Katz, MD, FACS, Chief Medical Officer.

Presentation details for SIR 2024 are as follows:

Presentation: Clinical Efficacy of Pressure-Enabled Transarterial Embolization of Hypovascular, Treatment-Refractory Metastases.
Presenting Author: Koustav Pal, MBBS, Postdoctoral Research Fellow at University of Texas MD Anderson Cancer Center
Date: Sunday, March 24, 2024
Time: 3:54 p.m. MT
Location: Salt Lake Palace Convention Center, Room 255C

Presentation: The PERIO-03 Trial: Technical Feasibility and Safety of a Novel Pancreatic Retrograde Venous Immunotherapy Infusion Intervention for Locally Advanced Pancreatic Ductal Adenocarcinoma.
Presenting Author: Rahul A. Sheth, MD, Associate Professor at University of Texas MD Anderson Cancer Center
Date: Sunday, March 24, 2024
Time: 4:21 p.m. MT
Location: Salt Lake Palace Convention Center, Room 255B

The presentations will be available on the publications page of the TriSalus website following the respective sessions.